Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review

References

• American Autoimmune Related Diseases Association, Inc. 2011. The cost burden of autoimmune disease: the latest front in the war on healthcare spending. Available at: http://www.aarda.org/pdf/cbad.pdf
   Google Scholar
• Vizcarra, C., and D. Belcher. 2006. Management of the patient receiving parenteral biologic therapy. J. Infus. Nurs. 29: 63–71
   Google Scholar
• Marquardt, J. L., Jr. R. H. Begent, K. Chester, et al. 2012. IBC's 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of the Antibody Society: December 2–6, 2012, San Diego, CA. MAbs. 4: 648–652
   Google Scholar
• Reichert, J. M. 2013. Which are the antibodies to watch in 2013? MAbs. 5: 1–4
   PubMed Web of Science ®Google Scholar
• Ackermann, C., and A. Kavanaugh. 2007. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin. Ther. Targets. 11: 1369–1384
   PubMed Web of Science ®Google Scholar
• Chang, J. T., and G. R. Lichtenstein. 2006. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 220–228
   PubMedGoogle Scholar
• Myers, W. A., A. B. Gottlieb, and P. Mease. 2006. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin. Dermatol. 24: 438–447
   PubMed Web of Science ®Google Scholar
• Bennett, A. N., A. L. Tan, L. C. Coates, et al. (2008). Sustained response to anakinra in ankylosing spondylitis. Rheumatology (Oxford). 47: 223–224
   PubMed Web of Science ®Google Scholar
• Haibel, H., M. Rudwaleit, J. Listing, and J. Sieper. 2005. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann. Rheum. Dis. 64: 296–298
   PubMed Web of Science ®Google Scholar
• Kiltz, U., F. Heldmann, X. Baraliakos, and J. Braun. 2012. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives? Curr. Opin. Rheumatol. 24: 252–260
   PubMed Web of Science ®Google Scholar
• Shealy, D., A. Cai, K. Staquet, et al. 2010. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs. 2: 428–439
   PubMed Web of Science ®Google Scholar
• Blick, S. K., and M. P. Curran. 2007. Certolizumab pegol: in Crohn's disease. BioDrugs. 21: 195–201; discussion 202–203
   PubMed Web of Science ®Google Scholar
• Kerensky T. A., A. B. Gottlieb, S. Yaniv, and S. C. Au. 2012. Etanercept: efficacy and safety for approved indications. Expert Opin. Drug Saf. 11: 121–139
   PubMed Web of Science ®Google Scholar
• Trinchard-Lugan, I., Q. Ho-Nguyen, W. M. Bilham, et al. 2001. Safety, pharmacokinetics and pharmacodynamics of recombinant human tumour necrosis factor-binding protein-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers. Eur. Cytokine Netw. 12: 391–398
   PubMed Web of Science ®Google Scholar
• Papp, K. 2010. Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis. Curr. Med. Res. Opin. 26: 2287–2300
   PubMed Web of Science ®Google Scholar
• Tracey, D., L. Klareskog, E. H. Sasso, et al. 2008. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117: 244–279
   PubMed Web of Science ®Google Scholar
• Okuda, Y. 2008. Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics. 2: 75–82
   PubMedGoogle Scholar
• Smolen, J. S., M. M. Schoels, N. Nishimoto, et al. 2013. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann. Rheum. Dis. 72: 482–492
   PubMed Web of Science ®Google Scholar
• Buch, M. H., J. S. Smolen, N. Betteridge, et al.; Rituximab Consensus Expert Committee. 2011. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70: 909–920
   PubMed Web of Science ®Google Scholar
• Genovese, M. C., E. Lee, J. Satterwhite, et al. 2013. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 72: 1453–1460
   PubMed Web of Science ®Google Scholar
• Schiff, M., M. Keiserman, C. Codding, et al. 2008. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 67: 1096–1103
   PubMed Web of Science ®Google Scholar
• Keystone, E. C., J. M. Kremer, A. Russell, et al. 2012. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann. Rheum. Dis. 71: 857–861
   PubMed Web of Science ®Google Scholar
• Mease, P. J., D. D. Gladman, E. C. Keystone, and Alefacept in Psoriatic Arthritis Study Group. 2006. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 54: 1638–1645
   PubMed Web of Science ®Google Scholar
• Talamonti, M., G. Spallone, A. Di Stefani, et al. 2011. Efalizumab. Expert Opin. Drug Saf. 10: 239–251
   PubMed Web of Science ®Google Scholar
• Tak, P. P., A. Balanescu, V. Tseluyko, et al. 2013. Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann. Rheum. Dis. 72: 337–344
   PubMed Web of Science ®Google Scholar
• Kane, S. V., S. Horst, W. J. Sandborn, et al. 2012. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm. Bowel Dis. 18: 2203–2208
   PubMed Web of Science ®Google Scholar
• Leonardi, C. L., A. B. Kimball, K. A. Papp, et al.; PHOENIX 1 study investigators. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 371: 1665–1674
   PubMed Web of Science ®Google Scholar
• Papp, K. A., R. G. Langley, M. Lebwohl, et al.; PHOENIX 2 study investigators. 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 371: 1675–1684
   PubMed Web of Science ®Google Scholar
• Gottlieb, A., A. Menter, A. Mendelsohn, et al. 2009. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 373: 633–640
   PubMed Web of Science ®Google Scholar
• EMA. 2006. Questions and answers on biosimilar medicines (similar biological medicinal products). Available at: www.emea.europa.eu/pdfs/human/pcwp/7456206en.pdf
   Google Scholar
• Rathore, A. S. 2009. Follow-on protein products: scientific issues, developments and challenges. Trends Biotechnol. 27: 698–705
   PubMed Web of Science ®Google Scholar
• Garces, S., J. Demengeot, and E. Benito-Garcia. 2013. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann. Rheum. Dis. 72: 1947–1955
   PubMed Web of Science ®Google Scholar
• Vincent, F. B., E. F. Morand, K. Murphy, et al. 2013. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann. Rheum. Dis. 72: 165–178
   PubMed Web of Science ®Google Scholar
• Robinson, C. J., and C. Jones. 2011. Quality control and analytical techniques for biopharmaceuticals. Bioanalysis. 3: 81–95
   Google Scholar
• Lee, J. F., J. B. Litten, and G. Grampp. 2012. Comparability and biosimilarity: considerations for the healthcare provider. Curr. Med. Res. Opin. 28: 1053–1058
   PubMed Web of Science ®Google Scholar
• Sahoo, N., K. Choudhury, and P. Manchikanti. 2009. Manufacturing of biodrugs: need for harmonization in regulatory standards. BioDrugs. 23: 217–229
   PubMed Web of Science ®Google Scholar
• Kozlowski, S., and P. Swann. 2009. Considerations for biotechnology product quality by design. In Quality by Design for Biopharmaceuticals: Principles and Case Studies. A. S. Rathore and R. Mhatre, eds. Wiley Interscience, NJ, USA. p. 9–30
   Google Scholar
• Schellekens, H. 2005. Follow-on biologics: challenges of the “next generation”. Nephrol. Dial. Transplant. 20: iv31–36
   PubMedGoogle Scholar
• Walsh, G., and R. Jefferis. 2006. Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol. 24: 1241–1252
   PubMed Web of Science ®Google Scholar
• Barosi, G., A. Bosi, M. P. Abbracchio, et al. 2011. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica. 96: 937–942
   PubMed Web of Science ®Google Scholar
• Mellstedt, H., D. Niederwieser, and H. Ludwig. 2008. The challenge of biosimilars. Ann. Oncol. 19: 411–419
   PubMed Web of Science ®Google Scholar
• Bartelds, G. M., C. A. Wijbrandts, M. T. Nurmohamed, et al. 2010. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann. Rheum. Dis. 69: 817–821
   PubMed Web of Science ®Google Scholar
• Breban, M., P. Ravaud, P. Claudepierre, et al.; French Ankylosing Spondylitis Infliximab Network. 2008. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum. 58: 88–97
   PubMed Web of Science ®Google Scholar
• Kuhlmann, M., and A. Covic. 2006. The protein science of biosimilars. Nephrol. Dial. Transplant. 21: v4–8
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Service, FDA. 2006. Guidance for Industry: Q9 Quality Risk Management. Available at: http://www.fda.gov/downloads/Drugs/…/Guidances/ucm073511.pdf
   Google Scholar
• Covic, A., J. Cannata-Andia, G. Cancarini, et al. 2008. Biosimilars and biopharmaceuticals: what the nephrologists need to know–a position paper by the ERA-EDTA Council. Nephrol. Dial. Transplant. 23: 3731–3737
   PubMed Web of Science ®Google Scholar
• No author listed. 2008. Quality risk management for aseptic processes. Technical report No. 44. PDA J. Pharm. Sci.Technol. 62: 2–39
   Google Scholar
• Schellekens, H. 2009. Biosimilar therapeutics—what do we need to consider? NDT Plus. 2: i27–i36
   PubMedGoogle Scholar
• Nakajima, K. 2012. Critical role of the interleukin-23/T-helper 17 cell axis in the pathogenesis of psoriasis. J. Dermatol. 39: 219–224
   PubMed Web of Science ®Google Scholar
• Gottlieb, S. L., P. Gilleaudeau, R. Johnson, et al. 1995. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1: 442–447
   PubMed Web of Science ®Google Scholar
• Wrone-Smith, T., and B. J. Nickoloff. 1996. Dermal injection of immunocytes induces psoriasis. J. Clin. Invest. 98: 1878–1887
   PubMed Web of Science ®Google Scholar
• Kess, D., T. Peters, J. Zamek, et al. 2003. CD4+ T cell-associated pathophysiology critically depends on CD18 gene dose effects in a murine model of psoriasis. J. Immunol. 171: 5697–5706
   Google Scholar
• Rivas Bejarano, J. J., and W. C. Valdecantos. 2013. Psoriasis as autoinflammatory disease. Dermatol. Clin. 31: 445–460
   PubMed Web of Science ®Google Scholar
• Foulkes, A. C., D. J. Grindlay, C. E. Griffiths, and R. B. Warren. 2011. What's new in psoriasis? An analysis of guidelines and systematic reviews published in 2009–2010. Clin. Exp. Dermatol. 36: 585–589 (quiz 588–589)
   PubMedGoogle Scholar
• Davidovici, B. B., N. Sattar, J. Prinz, et al. 2010. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J. Invest. Dermatol. 130: 1785–1796
   PubMed Web of Science ®Google Scholar
• Gladman, D. D., C. Antoni, P. Mease, et al. 2005. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis. 64: ii14–17
   PubMed Web of Science ®Google Scholar
• Kurd, S. K., A. B. Troxel, P. Crits-Christoph, and J. M. Gelfand. 2010. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch. Dermatol. 146: 891–895
   PubMed Web of Science ®Google Scholar
• Christophers, E., J. N. Barker, C. E. Griffiths, et al. 2010. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J. Eur. Acad. Dermatol. Venereol. 24: 548–554
   PubMed Web of Science ®Google Scholar
• Wolff, K., R. A. Johson, and D. Suurmond. 2005. Fitzpatrick’s Color Atlas & Synopsis of Clinical Dermatology. 5th ed., McGraw-Hill, New York
   Google Scholar
• Lowes, M. A., T. Kikuchi, J. Fuentes-Duculan, et al. 2008. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 128: 1207–1211
   PubMed Web of Science ®Google Scholar
• Nograles, K. E., R. D. Brasington, and A. M. Bowcock. 2009. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat. Clin. Pract. Rheumatol. 5: 83–91
   PubMedGoogle Scholar
• Lowes, M. A., A. M. Bowcock, and J. G. Krueger. 2007. Pathogenesis and therapy of psoriasis. Nature. 445: 866–873
   PubMed Web of Science ®Google Scholar
• Nestle, F. O., C. Conrad, A. Tun-Kyi, et al. 2005. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J. Exp. Med. 202: 135–143
   PubMed Web of Science ®Google Scholar
• Nograles, K. E., L. C. Zaba, E. Guttman-Yassky, et al. 2008. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 159: 1092–1102
   PubMed Web of Science ®Google Scholar
• Zaba, L. C., I. Cardinale, P. Gilleaudeau, et al. 2007. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204: 3183–3194
   PubMed Web of Science ®Google Scholar
• Prieto-Pérez, R., T. Cabaleiro, E. Daudén, et al. 2013. Genetics of psoriasis and pharmacogenetics of biological drugs. Autoimmune Dis. 2013: 613086
   Google Scholar
• Puig, L., J. M. Carrascosa, G. Carretero, et al.; Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. 2013. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Actas. Dermosifiliogr. 104: 694–709
   PubMedGoogle Scholar
• Nast, A., W. H. Boehncke, U. Mrowietz, et al.; Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). 2012. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J. Dtsch. Dermatol. Ges. 10: S1–S95
   Web of Science ®Google Scholar
• Salvarani, C., N. Pipitone, A. Marchesoni, et al.; Italian Society for Rheumatology. 2011. Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin. Exp. Rheumatol. 29: S28–S41
   PubMed Web of Science ®Google Scholar
• Gossec, L., J. S. Smolen, C. Gaujoux-Viala, et al.; European League Against Rheumatism. 2012. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann. Rheum. Dis. 71: 4–12
   PubMed Web of Science ®Google Scholar
• Smith, C. H., A. V. Anstey, J. N. Barker, et al.; (Chair of Guideline Group). 2009. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br. J. Dermatol. 161: 987–1019
   PubMed Web of Science ®Google Scholar
• Hsu, S., K. A. Papp, M. G. Lebwohl, et al.; National Psoriasis Foundation Medical Board. 2012. Consensus guidelines for the management of plaque psoriasis. Arch. Dermatol. 148: 95–102
   PubMed Web of Science ®Google Scholar
• Reich, K. 2012. The concept of psoriasis as a systemic inflammation: implications for disease management. J. Eur. Acad. Dermatol. Venereol. 26: 3–11
   PubMed Web of Science ®Google Scholar
• Turesson, C., W. M. O'Fallon, C. S. Crowson, et al. 2003. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann. Rheum. Dis. 62: 722–727
   PubMed Web of Science ®Google Scholar
• Pisetsky, D. S., and M. M. Ward. 2012. Advances in the treatment of inflammatory arthritis. Best Pract. Res. Clin. Rheumatol. 26: 251–261
   PubMed Web of Science ®Google Scholar
• Aletaha, D., T. Neogi, A. J. Silman, et al. 2010. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62: 2569–2581
   PubMed Web of Science ®Google Scholar
• Arnett, F. C., S. M. Edworthy, D. A. Bloch, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315–324
   PubMed Web of Science ®Google Scholar
• Bultink, I. E., M. Vis, I. E. van der Horst-Bruinsma, and W. F. Lems. 2012. Inflammatory rheumatic disorders and bone. Curr. Rheumatol. Rep. 14: 224–230
   PubMed Web of Science ®Google Scholar
• Inman, R. D., and H. S. El-Gabalawy. 2009. The immunology of ankylosing spondylitis and rheumatoid arthritis: a tale of similarities and dissimilarities. Clin. Exp. Rheumatol. 27: S26–S32
   Google Scholar
• Finnegan, A., S. Ashaye, and K. M. Hamel. 2012. B effector cells in rheumatoid arthritis and experimental arthritis. Autoimmunity. 45: 353–363
   PubMed Web of Science ®Google Scholar
• Lundy, S. K., S. Sarkar, L. A. Tesmer, and D. A. Fox. 2007. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Res. Ther. 9: 202
   PubMed Web of Science ®Google Scholar
• Aggarwal, A., A. Sharma, and A. Bhatnagar. 2013. Bi(o)communications among peripheral blood fractions: a focus on NK and NKT cell biology in rheumatoid arthritis. Autoimmunity. 46: 238–250
   PubMed Web of Science ®Google Scholar
• Choi, S. I., and E. Brahn. 2010. Rheumatoid arthritis therapy: advances from bench to bedside. Autoimmunity. 43: 478–492
   PubMed Web of Science ®Google Scholar
• Ruderman, E. M., K. M. Nola, S. Ferrell, et al. 2012. Incorporating the treat-to-target concept in rheumatoid arthritis. J. Manag. Care Pharm. 18: 1–18
   Google Scholar
• Atzeni, F., M. Benucci, S. Salli, et al. 2013. Different effects of biological drugs in rheumatoid arthritis. Autoimmun. Rev. 12: 575–579
   PubMed Web of Science ®Google Scholar
• Ozgocmen, S., and M. A. Khan. 2012. Current concept of spondyloarthritis: special emphasis on early referral and diagnosis. Curr. Rheumatol. Rep. 14: 409–414
   Google Scholar
• Poddubnyy, D., and M. Rudwaleit. 2012. Early spondyloarthritis. Rheum. Dis. Clin. North Am. 38: 387–403
   PubMed Web of Science ®Google Scholar
• Rudwaleit, M., D. van der Heijde, R. Landewe. 2009. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis. 68: 777–783
   PubMed Web of Science ®Google Scholar
• Rudwaleit, M., D. van der Heijde, R. Landewe, et al. 2011. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann. Rheum. Dis. 70: 25–31
   PubMed Web of Science ®Google Scholar
• Amor, B., M. Dougados, and M. Mijiyawa. 1990. Criteria of the classification of spondylarthropathies. Rev. Rhum. Mal. Osteoartic. 57: 85–89
   PubMedGoogle Scholar
• Dougados, M., S. van der Linden, R. Juhlin, et al. 1991. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 34: 1218–1227
   PubMed Web of Science ®Google Scholar
• van der Heijde, D., J. Sieper, W. P. Maksymowych, et al.; Assessment of SpondyloArthritis International Society. 2011. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann. Rheum. Dis. 70: 905–908
   PubMed Web of Science ®Google Scholar
• Braun, J., R. van den Berg, X. Baraliakos, et al. 2011. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 70: 896–904
   PubMed Web of Science ®Google Scholar
• Elewaut D., and M. Matucci-Cerinic. 2009. Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford). 48: 1029–1035
   PubMed Web of Science ®Google Scholar
• Sherlock, J. P., C. D. Buckley, and D. J. Cua. 2014. The critical role of interleukin-23 in spondyloarthropathy. Mol. Immunol. 57: 38–43
   PubMed Web of Science ®Google Scholar
• Robinson P. C., and M. A. Brown. 2013. The genetics of ankylosing spondylitis and axial spondyloarthritis. Rheum. Dis. Clin. North Am. 38: 539–553
   Google Scholar
• Seregin, S. S., D. P. Rastall, I. Evnouchidou, et al. 2013. Endoplasmic reticulum aminopeptidase-1 alleles associated with increased risk of ankylosing spondylitis reduce HLA-B27 mediated presentation of multiple antigens. Autoimmunity. 46: 497–508
   PubMed Web of Science ®Google Scholar
• Baraliakos X. and J. Braun. 2011. Spondyloarthritides. Best Pract. Res. Clin. Rheumatol. 25: 825–842
   PubMed Web of Science ®Google Scholar
• Zochling, J., D. van der Heijde, R. Burgos-Vargas, et al.; ‘ ASsessment in AS' international working group; European League Against Rheumatism. 2006. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 65: 442–452
   PubMed Web of Science ®Google Scholar
• Adams, K., C. Bombardier, and D. van der Heijde. 2012. Safety and efficacy of on-demand versus continuous use of nonsteroidal antiinflammatory drugs in patients with inflammatory arthritis: a systematic literature review. J. Rheumatol. Suppl. 90: 56–58
   Google Scholar
• Baraliakos, X., and J. Braun. 2012. Biologic therapies for spondyloarthritis: what is new? Curr. Rheumatol. Rep. 14: 422–427
   PubMedGoogle Scholar
• Scarpa, R., A. Cuocolo, R. Peluso, et al. 2008. Early psoriatic arthritis: the clinical spectrum. J. Rheumatol. 35: 137–141
   PubMed Web of Science ®Google Scholar
• Ruiz, D. G., M. N. Azevedo, and O. L. Santos. 2012. Psoriatic arthritis: a clinical entity distinct from psoriasis? Rev. Bras. Reumatol. 52: 630–638
   Google Scholar
• Taylor, W., D. Gladman, P. Helliwell, et al.; CASPAR Study Group. 2006. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 54: 2665–2673
   PubMed Web of Science ®Google Scholar
• Hsieh, J., S. Kadavath, and P. Efthimiou. 2013. Can traumatic injury trigger psoriatic arthritis? A review of the literature. Clin. Rheumatol. [Epub ahead of print]
   Google Scholar
• Maeda, S., Y. Hayami, T. Naniwa, and R. Ueda. 2012. The Th17/IL-23 Axis and natural immunity in psoriatic arthritis. Int. J. Rheumatol. 2012: 539683
   Google Scholar
• Kavanaugh, A. F., C. T. Ritchlin, and G. T. G. Committee. 2006. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J. Rheumatol. 33: 1417–1421
   PubMed Web of Science ®Google Scholar
• Chang, C. A., A. B. Gottlieb, and P. F. Lizzul. 2011. Management of psoriatic arthritis from the view of the dermatologist. Nat. Rev. Rheumatol. 7: 588–598
   PubMedGoogle Scholar
• Barr, A., and A. Keat. 2010. Spondyloarthritides: evolving therapies. Arthritis Res. Ther. 12: 221
   PubMedGoogle Scholar
• Soriano, E. R. 2012. The actual role of therapy with traditional disease-modifying antirheumatic drugs in psoriatic arthritis. J. Rheumatol. 89: 67–70
   Google Scholar
• Ash, Z., C. Gaujoux-Viala, L. Gossec, et al. 2012. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann. Rheum. Dis. 71: 319–326
   PubMed Web of Science ®Google Scholar
• Mease, P. J., B. S. Goffe, J. Metz, et al. 2000. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 356: 385–390
   PubMed Web of Science ®Google Scholar
• Mease, P. J., A. J. Kivitz, F. X. Burch, et al. 2004. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 50: 2264–2272
   PubMed Web of Science ®Google Scholar
• Antoni, C. E., A. Kavanaugh, B. Kirkham, et al. 2005. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 52: 1227–1236
   PubMed Web of Science ®Google Scholar
• Mease, P. J., D. D. Gladman, C. T. Ritchlin, et al.; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group. 2005. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52: 3279–3289
   PubMed Web of Science ®Google Scholar
• Kavanaugh, A., I. McInnes, P. Mease, et al. 2009. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 60: 976–986
   PubMed Web of Science ®Google Scholar
• Atzeni, F., P. Sarzi-Puttini, and G. A. Vena. 2009. Resistant cases of psoriatic arthritis: how to manage them. J. Rheumatol. 83: 73–75
   Google Scholar
• Gottlieb, A., and K. Narang. 2013. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. Ther. Adv. Musculoskelet. Dis. 5: 277–285
   PubMedGoogle Scholar
• Atzeni, F., D. Ventura, A. Batticciotto, et al. 2012. Interleukin 6 blockade: tocilizumab in psoriatic arthritis. J. Rheumatol. 89: 97–99
   Google Scholar
• Schafer, P. 2012. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem. Pharmacol. 83: 1583–1590
   PubMed Web of Science ®Google Scholar
• Podolsky, D. K. 2002. Inflammatory bowel disease. N. Engl. J. Med. 347: 417–429
   PubMed Web of Science ®Google Scholar
• Baumgart, D. C., and W. J. Sandborn. 2012. Crohn's disease. Lancet. 380: 1590–1605
   PubMed Web of Science ®Google Scholar
• Ordas, I., L. Eckmann, M. Talamini, et al. 2012. Ulcerative colitis. Lancet. 380: 1606–1619
   PubMed Web of Science ®Google Scholar
• Silverberg, M. S., J. Satsangi, T. Ahmad, et al. 2005. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. 19: 5–36
   PubMed Web of Science ®Google Scholar
• Khor, B., A. Gardet, and R. J. Xavier. 2011. Genetics and pathogenesis of inflammatory bowel disease. Nature. 474: 307–317
   PubMed Web of Science ®Google Scholar
• Raza, A., W. Yousaf, R. Giannella, and M. T. Shata. 2012. Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease. Expert Rev. Clin. Immunol. 8: 161–168
   PubMed Web of Science ®Google Scholar
• Cosnes, J., C. Gower-Rousseau, P. Seksik, and A. Cortot. 2011. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 140: 1785–1794
   PubMed Web of Science ®Google Scholar
• Hoivik, M. L., T. Bernklev, I. C. Solberg, et al.; IBSEN Study Group. 2012. Patients with Crohn's disease experience reduced general health and vitality in the chronic stage: ten-year results from the IBSEN study. J. Crohns Colitis. 6: 441–453
   PubMed Web of Science ®Google Scholar
• McGovern, D., and F. Powrie. 2007. The IL23 axis plays a key role in the pathogenesis of IBD. Gut. 56: 1333–1336
   PubMed Web of Science ®Google Scholar
• Ivanov, I. I., L. Frutos Rde, N. Manel, et al. 2008. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe. 4: 337–349
   PubMed Web of Science ®Google Scholar
• Monteleone, G., I. Monteleone, D. Fina, et al. 2005. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology. 128: 687–694
   PubMed Web of Science ®Google Scholar
• Shih, D. Q., S. R. Targan, and D. McGovern. 2008. Recent advances in IBD pathogenesis: genetics and immunobiology. Curr. Gastroenterol. Rep. 10: 568–575
   PubMedGoogle Scholar
• Hisamatsu, T., T. Kanai, Y. Mikami, et al. 2013. Immune aspects of the pathogenesis of inflammatory bowel disease. Pharmacol. Ther. 137: 283–297
   PubMed Web of Science ®Google Scholar
• Danese, S. 2012. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut. 61: 918–932
   PubMed Web of Science ®Google Scholar
• Orlando, A., A. Armuzzi, C. Papi, et al.; Italian Society of Gastroenterology; Italian Group for the study of Inflammatory Bowel Disease. 2011. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig. Liver Dis. 43: 1–20
   PubMedGoogle Scholar
• Dignass, A., G. Van Assche, J. O. Lindsay, et al.; European Crohn's and Colitis Organisation (ECCO). 2010. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J. Crohns Colitis. 4: 28–62
   PubMed Web of Science ®Google Scholar
• Dignass, A., J. O. Lindsay, A. Sturm, et al. 2012. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J. Crohns Colitis. 6: 991–1030
   PubMed Web of Science ®Google Scholar
• Ford, A. C., W. J. Sandborn, K. J. Khan, et al. 2011. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am. J. Gastroenterol. 106: 644–659. (quiz 660)
   PubMed Web of Science ®Google Scholar
• Schnitzler, F., H. Fidder, M. Ferrante, et al. 2009. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 58: 492–500
   PubMed Web of Science ®Google Scholar
• Ferrante, M., S. Vermeire, H. Fidder, et al. 2008. Long-term outcome after infliximab for refractory ulcerative colitis. J. Crohns Colitis. 2: 219–225
   PubMed Web of Science ®Google Scholar
• Tozer, P., S. C. Ng, M. R. Siddiqui, et al. 2012. Long-term MRI-guided combined anti-TNF-alpha and thiopurine therapy for Crohn's perianal fistulas. Inflamm. Bowel Dis. 18: 1825–1834
   PubMed Web of Science ®Google Scholar
• Tonelli, F., F. Giudici, and C. R. Asteria. 2012. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study. Dis. Colon Rectum. 55: 870–875
   PubMed Web of Science ®Google Scholar
• Seow, C. H., A. Newman, S. P. Irwin, et al. 2010. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 59: 49–54
   PubMed Web of Science ®Google Scholar
• Pariente, B., G. Pineton de Chambrun, R. Krzysiek, et al. 2012. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 18: 1199–1206
   PubMed Web of Science ®Google Scholar
• Vande Casteele, N., V. Ballet, G. Van Assche, et al. 2012. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut. 61: 321 (author reply 322)
   PubMed Web of Science ®Google Scholar
• D'Haens, G. R., R. Panaccione, P. D. Higgins, et al. 2011. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am. J. Gastroenterol. 106: 199–212 (quiz 213)
   PubMed Web of Science ®Google Scholar
• Louis, E., J. Y. Mary, G. Vernier-Massouille, et al.; Groupe D'etudes Therapeutiques Des Affections Inflammatoires Digestives. 2012. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 142: 63–70 e65 (quiz e31)
   PubMed Web of Science ®Google Scholar
• Colombel, J. F., W. J. Sandborn, W. Reinisch, et al.; SONIC Study Group. 2010. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362: 1383–1395
   PubMed Web of Science ®Google Scholar
• Panaccione, R., S. Ghosh, S. Middleton, et al. 2011. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: The UC SUCCESS trial. Gastroenterology. 140: S–134
   Google Scholar
• Van Assche, G., J. D. Lewis, G. R. Lichtenstein, et al. 2011. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am. J. Gastroenterol. 106: 1594–1602 (quiz 1593, 1603)
   PubMed Web of Science ®Google Scholar
• Epis, O. M., L. Giacomelli, S. Deidda, and E. Bruschi. 2012. Tight control applied to the biological therapy of rheumatoid arthritis. Autoimmun. Rev. 12: 839–841
   Google Scholar
• Pink, A. E., A. Fonia, M. H. Allen, et al. 2010. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br. J. Dermatol. 162: 780–785
   PubMed Web of Science ®Google Scholar
• Bartelds, G. M., C. A. Wijbrandts, M. T. Nurmohamed, et al. 2007. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann. Rheum. Dis. 66: 921–926
   PubMed Web of Science ®Google Scholar
• Moots, R. J., and B. Naisbett-Groet. 2012. The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology (Oxford). 51: 2252–2261
   PubMedGoogle Scholar
• Finckh, A., A. Ciurea, L. Brulhart, et al. 2010. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann. Rheum. Dis. 69: 387–393
   PubMed Web of Science ®Google Scholar
• Jamnitski, A., G. M. Bartelds, M. T. Nurmohamed, et al. 2011. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann. Rheum. Dis. 70: 284–288
   PubMed Web of Science ®Google Scholar
• ADOI-ISS. 2013. Linee guida – Il trattamento della Psoriasi nell'adulto. Milano: Zadig
   Google Scholar
• de Vries, M. K., I. E. van der Horst-Bruinsma, M. T. Nurmohamed, et al. 2009. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann. Rheum. Dis. 68: 531–535
   PubMed Web of Science ®Google Scholar
• Bendtzen, K., P. Geborek, M. Svenson, et al. 2006. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 54: 3782–3789
   PubMed Web of Science ®Google Scholar
• Papp, K. A., C. E. Griffiths, K. Gordon, et al.; PHOENIX 1 Investigators; PHOENIX 2 Investigators; ACCEPT Investigators. 2013. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br. J. Dermatol. 168: 844–854
   PubMed Web of Science ®Google Scholar
• Zhu, Y., C. Hu, M. Lu, et al. 2009. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J. Clin. Pharmacol. 49: 162–175
   PubMed Web of Science ®Google Scholar
• Mulleman, D., E. Ducourau, G. Paintaud, et al. 2012. Should anti-TNF-alpha drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis? Joint Bone Spine. 79: 109–112
   PubMed Web of Science ®Google Scholar
• Todoerti, M., N. Pipitone, M. Matucci-Cerinic, et al.; Italian Society for Rheumatology. 2011. Recommendations for the use of biologic therapy from the Italian Society for Rheumatology: off-label use. Clin. Exp. Rheumatol. 29: S42–S62
   Google Scholar
• Talamonti, M., E. Botti, M. Galluzzo, et al. 2013. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br. J. Dermatol. 169: 458–463
   PubMed Web of Science ®Google Scholar